You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

908 Results
Document
Jan 2021
Document
Jan 2021
Document
Jan 2021
Document
Jan 2021
Document
Jan 2021
Document
Jan 2021
Document
Jan 2021
Document
Jan 2021
Guidelines and Advice
Status: Current
ID: 7-A-2018-3
Feb 2021
Document
Feb 2021
Document
Feb 2021
Regimen
Cancer Type:
Genitourinary, 
Prostate
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    olaparib - For the treatment of metastatic castration resistant prostate cancer (mCRPC), based on criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
olaparib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2024

Pages